Evidence map›Paper›PMID 36178899›Full record

ArticlePloS one2022

A robust, low-cost instrument for real-time colorimetric isothermal nucleic acid amplification.

Frank B Myers, Brian Moffatt, Ragheb El Khaja, Titatsh Chatterjee, Gurmeet Marwaha, Max McGee, Debkishore Mitra

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Frank B MyersResearch & Development, Lucira Health, Inc., Emeryville, CA, United States of America.ORCID 0000-0003-4871-3213
Brian MoffattManufacturing Engineering, Lucira Health, Inc., Emeryville, CA, United States of America.ORCID 0000-0001-5721-0808
Ragheb El KhajaResearch & Development, Lucira Health, Inc., Emeryville, CA, United States of America.
Titatsh ChatterjeeResearch & Development, Lucira Health, Inc., Emeryville, CA, United States of America.
Gurmeet MarwahaQuality Control, Lucira Health Inc., Emeryville, CA, United States of America.
Max McGeeResearch & Development, Lucira Health, Inc., Emeryville, CA, United States of America.
Debkishore MitraResearch & Development, Lucira Health, Inc., Emeryville, CA, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has highlighted the need for broader access to molecular diagnostics. Colorimetric isothermal nucleic acid amplification assays enable simplified instrumentation over more conventional PCR diagnostic assays and, as such, represent a promising approach for addressing this need. In particular, colorimetric LAMP (loop-mediated isothermal amplification) has received a great deal of interest recently. However, there do not currently exist robust instruments for performing these kinds of assays in high throughput with real-time readout of amplification signals. To address this need, we developed LARI, the LAMP Assay Reader Instrument. We have deployed over 50 LARIs for routine use in R&D and production environments, with over 12,000 assays run to date. In this paper, we present the design and construction of LARI along with thermal, optical, and assay performance characteristics. LARI can be produced for under $1500 and has broad applications in R&D, point-of-care diagnostics, and global health.

Indexed as

COVID-19Nucleic AcidsColorimetryHumansMolecular Diagnostic TechniquesNucleic Acid Amplification TechniquesPandemicsSensitivity and SpecificityNucleic Acids

Identifiers

PMID36178899
PMCPMC9524685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.